Epigenetic plus cytokine therapy induces stem-like CD8 + T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance
Open Access
- 12 September 2026
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (9) , e015228
Abstract
Background: Checkpoint blockade (CPB) has limited efficacy in patients with colorectal cancer (CRC), warranting improved therapeutic strategies capable of remodeling the tumor microenvironment. Stem-like TCF1 + CD8 + T cells, cytotoxic CD8 + T cells, and lymphoid aggregates have been associated with CPB responsiveness, either individually or as coordinated immune hubs. Methods: We evaluated the combination of αPD-1, the class I histone deacetylase inhibitor entinostat, and the IL-15 superagonist N-803 in CPB-resistant murine CRC and breast cancer models with varying antigen presentation deficiencies. Proteomic, transcriptomic, spatial, and functional analyses were completed to identify treatment-specific immune remodeling. Translational relevance was assessed using publicly available CPB-treated cancer genomic datasets and functional assays with patient-derived peripheral blood mononuclear cells (PBMCs). Results: Triple therapy increased stem-like TCF1 + CD8 + T cells in tumor-draining lymph nodes and tumors, concomitant with increased intratumoral cytotoxic GZMB + CD8 + T cells. Therapeutic efficacy was associated with remodeling of the tumor microenvironment, uniquely marked by enrichment of intratumoral immune niches comprising TCF1 + and cytotoxic CD8 + T cells, type 1 conventional dendritic cells, and B cells, along with concerted cytokine and chemokine production. A transcriptional signature derived from triple therapy-induced immune niches predicted favorable clinical responses across multiple CPB-experienced cancer cohorts. These responses were functionally corroborated by increased markers of cytotoxicity in patient-derived PBMCs in vitro. Conclusions: Treatment with entinostat, N-803, and αPD-1 boosts anti-tumor intratumoral immune niches comprising TCF1 + CD8 + T cells. Collectively, these findings suggest that TCF1 + CD8 + T cell immune niches previously associated with αPD-1 responsiveness and lacking in non-responders, including most CRC patients, may be restored by the addition of entinostat and N-803 to αPD-1 therapy to treat αPD-1-refractory patients.Keywords
This publication has 56 references indexed in Scilit:
- Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancerCancer Cell, 2025
- A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunityCancer Cell, 2023
- Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinomaCancer Cell, 2023
- How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translationInternational Journal of Cancer, 2023
- Drug resistance in colorectal cancer: An epigenetic overviewBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Spatially organized multicellular immune hubs in human colorectal cancerCell, 2021
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionCell, 2021
- Plasma cells: The programming of an antibody‐secreting machineEuropean Journal of Immunology, 2018
- The Regulatory Role of IFN-γ on the Proliferation and Differentiation of Hematopoietic Stem and Progenitor CellsStem Cell Reviews and Reports, 2017
- Activation induced differential regulation of stem cell antigen-1 (Ly-6A/E) expression in murine B cellsCellular Immunology, 2003